Inhibition of the menin–MLL1 interaction has shown promise in disrupting leukemogenic transcriptional programs, especially in acute leukemias, but its role is now being explored in other hematologic malignancies such as diffuse large B-cell lymphoma, multiple myeloma, and CLL [126]. This evidence concerns the gene MEN1 and B-cell chronic lymphocytic leukemia.